Flu treatment and prevention drug linked to serious allergic reaction
A medicine used to treat and help prevent the flu may put patients at risk for a rare but life-threatening condition in which the skin peels off the body in sheets, according to the Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research. The agency notified the public that it has approved safety label changes for Relenza (zanamivir) Inhalation Powder for oral inhalation. The Adverse Reactions section of the drug’s new safety label now includes a risk of rash, including serious cutaneous reactions (e.g. erythema multiforme, Stevens Johnson Syndrome, SJS, and toxic epidermal necrolysis, TEN).
![[ Beasley Allen Law Firm Logo ]](http://www.sjs-legal.com/wp-content/themes/system-unity/images/logo.png)
A medication used for the management of hypertension now includes an updated safety label that warns patients of a rare but serious skin condition, according to the Food and Drug Administration (FDA)’s Safety Information and Adverse Event Reporting Program. The new safety label for Inderide (propranolol HCL/hydrochlorothiazide) tablets carries a warning of “erythema multiforme including
Drug maker Tibotec, which specializes in innovative therapeutic and diagnostic solutions for infectious diseases such as HIV/AIDS, is seeking approval from the FDA for its latest HIV treatment, Intelence, based on data from its phase-three studies of the drug when used in combination with other antiretroviral agents, according to a press release from